The
secondary objectives of this study in this study population are as
follows: To evaluate gastrointestinal-related events requiring
symptomatic therapy and the role of those therapies over time; To
evaluate gastrointestinal-related events that lead to a physician's
decision to manage the events with Tecfidera dose modification; and To
evaluate gastrointestinal-related events that lead to Tecfidera
discontinuation after the use of symptomatic therapy.
Story Source: The above story is based on materials provided by CLINICALTRIALS.GOV
Note: Materials may be edited for content and length
